Protein Kinase Inhibitors as a New Target for Immune System Modulation and Brain Cancer Management

Int J Mol Sci. 2022 Dec 10;23(24):15693. doi: 10.3390/ijms232415693.

Abstract

High-grade brain tumors are malignant tumors with poor survival and remain the most difficult tumors to treat. An important contributing factor to the development and progression of brain tumors is their ability to evade the immune system. Several immunotherapeutic strategies including vaccines and checkpoint inhibitors have been studied to improve the effectiveness of the immune system in destroying cancer cells. Recent studies have shown that kinase inhibitors, capable of inhibiting signal transduction cascades that affect cell proliferation, migration, and angiogenesis, have additional immunological effects. In this review, we explain the beneficial therapeutic effects of novel small-molecule kinase inhibitors and explore how, through different mechanisms, they increase the protective antitumor immune response in high-grade brain tumors.

Keywords: anti-tumor immunity; brain tumors; immune system; protein kinase inhibitor; tumor microenvironment.

Publication types

  • Review

MeSH terms

  • Brain Neoplasms* / drug therapy
  • Humans
  • Immune System
  • Immunity
  • Immunotherapy
  • Protein Kinase Inhibitors* / pharmacology
  • Protein Kinase Inhibitors* / therapeutic use
  • Signal Transduction
  • Tumor Microenvironment

Substances

  • Protein Kinase Inhibitors

Grants and funding

This research received no external funding.